NCT06716879

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

A Single-Center, Randomized, Investigator- and Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics After a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Donzakimig	Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
DRUG	Placebo	Drug: Placebo Pharmaceutical form: Subcutaneous solution

Timeline

• Start date: 2024-12-06
• Primary completion: 2025-04-04
• Completion: 2025-04-04
• First posted: 2024-12-04
• Last updated: 2026-02-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study